We are live on
!
Find out more
FFM
Fairmount Funds Management Portfolio holdings
AUM
$1.38B
1-Year Est. Return
407.79%
This Fund
S&P 500
This Quarter
Est. Return
-6.3%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$885M
AUM Growth
-$32.3M
(-3.5%)
Cap. Flow
+$73.3M
Cap. Flow
% of AUM
8.29%
Top 10 Holdings %
Top 10 Hldgs %
94.27%
Holding
16
New
1
Increased
2
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Spyre Therapeutics
SYRE
|
+$123M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
+$24.2M |
| 3 |
Cogent Biosciences
COGT
|
+$11.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$32.3M |
| 2 |
Tyra Biosciences
TYRA
|
+$22.9M |
| 3 |
Geron
GERN
|
+$22M |
| 4 |
TERN
Terns Pharmaceuticals
TERN
|
+$7.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$12.3B
| $190M | 21.46% |
2,360,077
| – | – |
|
|
NUVL
2
DELISTED
Nuvalent
NUVL
| $146M | 16.5% |
1,924,626
| – | – |
|
|
3
Spyre Therapeutics
SYRE
$8.69B
| $94.5M | 10.67% |
4,018,101
+3,639,680
| +962% | +$123M |
|
4
Apogee Therapeutics
APGE
$10.2B
| $80.6M | 9.11% |
2,048,647
| – | – |
|
5
Enliven Therapeutics
ELVN
$3.77B
| $74.8M | 8.46% |
3,202,798
| – | – |
|
6
Dianthus Therapeutics
DNTH
$5.71B
| $71.5M | 8.08% |
2,762,837
| – | – |
|
7
Kiniksa Pharmaceuticals
KNSA
$4.89B
| $59.8M | 6.76% |
3,204,841
| – | – |
|
|
8
Cogent Biosciences
COGT
$6.91B
| $52.5M | 5.93% |
6,225,641
+1,500,000
| +32% | +$11.4M |
|
|
ATXS
9
DELISTED
Astria Therapeutics
ATXS
| $32.3M | 3.65% |
3,554,129
| – | – |
|
10
Protagonist Therapeutics
PTGX
$8.72B
| $32.3M | 3.65% |
931,890
| – | – |
|
11
Viridian Therapeutics
VRDN
$2.18B
| $24M | 2.71% |
1,845,813
| – | – |
|
|
BCYC
12
Bicycle Therapeutics
BCYC
$276M
| $21.6M | 2.44% |
+1,069,199
| New | +$24.2M |
|
|
TERN
13
DELISTED
Terns Pharmaceuticals
TERN
| $5.1M | 0.58% |
748,996
-1,291,004
| -63% | -$7.82M |
|
|
14
Geron
GERN
$949M
| – | – |
-6,666,667
| Closed | -$22M |
|
|
MRUS
15
DELISTED
Merus
MRUS
| – | – |
-717,254
| Closed | -$32.3M |
|
|
16
Tyra Biosciences
TYRA
$1.85B
| – | – |
-1,393,329
| Closed | -$22.9M |
|
Similar funds
NIP
OCAM
AU
RIM
VC
AO
1CP
OCM
Fairmount Funds Management's Q2 2024 Portfolio in Review
As of Q2 2024, Fairmount Funds Management held 16 positions worth $885M, down 3.5% from $917M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
Fairmount Funds Management deployed $73.3M of net new capital in Q2 2024, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Bicycle Therapeutics: 1,069,199 shares worth $21.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $7.82M trimmed.
- Fairmount Funds Management's largest Q2 2024 buy was Bicycle Therapeutics: 1,069,199 shares worth $21.6M.
- Fairmount Funds Management added most to Spyre Therapeutics in Q2 2024, an estimated $123M increase.
- Fairmount Funds Management's biggest Q2 2024 reduction was Terns Pharmaceuticals, cutting an estimated $7.82M.
- Fairmount Funds Management fully exited Merus in Q2 2024, selling an estimated $32.3M.
- Fairmount Funds Management's ten largest holdings make up 94% of its $885M portfolio in Q2 2024.
- Fairmount Funds Management opened 1 new position and closed 3 in Q2 2024.
- Fairmount Funds Management's portfolio value fell 3.5% quarter-over-quarter to $885M.
Based on Fairmount Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.